PROPAFENONE IN THE TREATMENT OF CARDIAC-ARRHYTHMIAS - A RISK-BENEFIT APPRAISAL

被引：24

作者：

CAPUCCI, A

BORIANI, G

机构：

[1] Institute of Cardiovascular Disease, University of Bologna, Bologna, 40138

来源：

DRUG SAFETY | 1995年 / 12卷 / 01期

关键词：

D O I：

10.2165/00002018-199512010-00005

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Propafenone is a potent antiarrhythmic agent effective in either supraventricular or ventricular tachyarrhythmias. For proper utilisation, some important pharmacological aspects must be considered, such as nonlinear pharmacokinetics, inability in some patients (poor debrisoquine metabolisers) to oxidise the drug in the liver, existence of at least one active metabolite (5-hydroxy-propafenone) and ability to exert a slight beta-blocking activity. Like all the other antiarrhythmic drugs, propafenone may be associated with adverse effects and may exert proarrhythmic effects. For this reason, its usage must be based on a careful analysis of the risk-benefit ratio, by considering the patient's profile as well as the characteristics of the arrhythmia and its prognostic significance. Propafenone appears to be very effective, and has a favourable risk-benefit profile in the treatment of all supraventricular arrhythmias. Particularly, it is effective in converting atrial fibrillation to sinus rhythm and in preventing atrial fibrillation recurrences, and is very effective in the pharmacological control of the arrhythmias of the Wolff-Parkinson-White syndrome. Propafenone is also effective in suppressing ventricular premature complexes and nonsustained ventricular tachycardias. However, because of potential proarrhythmic effects, its use in these arrhythmias must be considered after a careful analysis of the risk-benefit profile, which could be favourable in some patients, but less favourable in others (e.g. patients with coronary artery disease and ventricular dysfunction). In malignant ventricular arrhythmias, further studies are needed to define the limitations of antiarrhythmic drugs in comparison with non-pharmacological treatments, mainly cardioverter/defibrillators. At present, like the other class I antiarrhythmic agents, propafenone does not seem to be a first choice prophylactic agent for malignant ventricular arrhythmias, although more data from controlled studies are needed.

引用

页码：55 / 72

页数：18

共 105 条

[1]

Vaughan Willia E.M., A classifications of antiarrhythmic actions reassessed after a decade of new drugs, J Clin Pharmacol, 24, (1984)

[2]

Hollman M., Brode E., Holtz D., Et al., Investigation on the pharmacokinetics of propafenone in man, Arzneimittelforschung, 33, (1983)

[3]

Connolly S.J., Kates R.E., Lebsack C.S., Et al., Clinical pharmacology of propafenone, Circulation, 68, (1983)

[4]

Hege H.G., Hollman M., Kavmeier S., Et al., The metabolic fate of 3H-labelled propafenone in man, Eur J Drug Metab Pharmacokinet, 9, pp. 41-55, (1984)

[5]

Kates R.E., Yee Y.G., Winkle R.A., Metabolite cumulation during chronic propafenone dosing in arrhythmia, Clin Pharmacol Ther, 37, (1985)

[6]

Siddoway L.A., Thompson K.A., McAllister C.B., Et al., Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences, Circulation, 75, (1987)

[7]

Kroemer H.K., Funck-Bentano C., Silberstein D.J., Et al., Stereoselective disposition and pharmacologic activity of propafenone enantiomers, Circulation, 79, (1989)

[8]

Lennard M.S., Silas J.H., Freestone S., Et al., Oxidation phenotype. A major determinant of metoprolol metabolism and response, N Engl J Med, 307, (1982)

[9]

Kalow W., Ethnic differences in drug metabolism, Clin Pharmacokinet, 7, pp. 373-400, (1982)

[10]

Clark D.W.J., Genetically determined variability in acetylation and oxidation. Therapeutic implications, Drugs, 29, (1985)

← 1 2 3 4 5 6 7 8 9 10 →